Suppr超能文献

G 蛋白偶联受体结构与功能关系:偏倚性阿片肽受体突变体的鉴定。

GPCR structure and function relationship: identification of a biased apelin receptor mutant.

机构信息

Amgen Asia R&D Center, Amgen Biopharmaceutical R&D (Shanghai) Co., Ltd, Shanghai 201210, China.

Amgen Research, Amgen Inc., One Amgen Center Dr., Thousand Oaks, CA 91320, U.S.A.

出版信息

Biochem J. 2018 Dec 6;475(23):3813-3826. doi: 10.1042/BCJ20180740.

Abstract

Biased ligands of G protein-coupled receptors (GPCRs) may have improved therapeutic benefits and safety profiles. However, the molecular mechanism of GPCR biased signaling remains largely unknown. Using apelin receptor (APJ) as a model, we systematically investigated the potential effects of amino acid residues around the orthosteric binding site on biased signaling. We discovered that a single residue mutation I109A (I109) in the transmembrane domain 3 (TM3) located in the deep ligand-binding pocket was sufficient to convert a balanced APJ into a G protein signaling biased receptor. APJ I109A mutant receptor retained full capabilities in ligand binding and G protein activation, but was defective in GRK recruitment, β-arrestin recruitment, and downstream receptor-mediated ERK activation. Based on molecular dynamics simulations, we proposed a molecular mechanism for biased signaling of I109A mutant receptor. We postulate that due to the extra space created by I109A mutation, the phenyl group of the last residue (Phe-13) of apelin rotates down and initiates a cascade of conformational changes in TM3. Phe-13 formed a new cluster of hydrophobic interactions with the sidechains of residues in TM3, including F110 and M113, which stabilizes the mutant receptor in a conformation favoring biased signaling. Interruption of these stabilizing interactions by double mutation F110A/I109A or M113A/I109A largely restored the β-arrestin-mediated signaling. Taken together, we describe herein the discovery of a biased APJ mutant receptor and provide detailed molecular insights into APJ signaling selectivity, facilitating the discovery of novel therapeutics targeting APJ.

摘要

G 蛋白偶联受体 (GPCR) 的偏倚配体可能具有更好的治疗效果和安全性。然而,GPCR 偏倚信号转导的分子机制在很大程度上仍不清楚。我们以阿片肽受体 (APJ) 为模型,系统研究了位于正位结合口袋深处的变构结合位点周围氨基酸残基对偏倚信号的潜在影响。我们发现,跨膜域 3 (TM3) 中单个残基突变 I109A (I109) 足以将平衡的 APJ 转化为 G 蛋白信号偏倚受体。APJ I109A 突变受体保留了配体结合和 G 蛋白激活的全部能力,但在 GRK 募集、β-arrestin 募集和下游受体介导的 ERK 激活方面存在缺陷。基于分子动力学模拟,我们提出了 I109A 突变受体偏倚信号的分子机制。我们假设,由于 I109A 突变产生的额外空间,阿片肽最后一个残基 (Phe-13) 的苯环向下旋转,并引发 TM3 构象变化的级联反应。Phe-13 与 TM3 中残基的侧链 (包括 F110 和 M113) 形成新的疏水相互作用簇,使突变受体稳定在有利于偏倚信号的构象中。通过双突变 F110A/I109A 或 M113A/I109A 中断这些稳定相互作用,在很大程度上恢复了β-arrestin 介导的信号。总之,我们在此描述了一种偏倚的 APJ 突变受体的发现,并提供了 APJ 信号选择性的详细分子见解,为靶向 APJ 的新型治疗药物的发现提供了便利。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验